300006.SZ SHZ
Chongqing Lummy Pharmaceutical Co., Ltd.
1W: +0.0%
1M: -2.6%
3M: +11.9%
YTD: +8.2%
1Y: +9.0%
3Y: +62.1%
5Y: -23.0%
¥5.56 ($0.83)
+0.26 (+4.91%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
$61M
-66.9% ▼
5Y CAGR: -22.9%
Capital Expenditures
$38M
+49.5% ▲
5Y CAGR: -2.6%
Free Cash Flow
$23M
-78.9% ▼
5Y CAGR: -33.7%
Dividends Paid
$0
+100.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$148M
-141.5% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$106M | -$76M | -$9M | -$80M | -$135M |
| Depreciation & Amort. | $75M | $76M | $75M | $56M | $54M |
| Stock-Based Comp. | $4M | $2M | $0 | $0 | $0 |
| Change in Working Capital | $114M | $66M | $34M | $165M | $36M |
| Other Non-Cash Items | $25M | -$9M | -$19M | $44M | $130M |
| Operating Cash Flow | $108M | $57M | $82M | $185M | $61M |
| — Investing Activities — | |||||
| Capital Expenditures | -$39M | -$68M | -$59M | -$76M | -$38M |
| Acquisitions (Net) | $78M | $1K | $12M | -$11M | $5M |
| Investment Purchases | -$92M | -$45M | -$13M | -$1M | -$40M |
| Investment Sales | $217M | $126M | $66M | $5M | $21M |
| Other Investing | -$7M | $1M | -$125M | $64M | -$4M |
| Investing Cash Flow | $157M | $14M | -$120M | -$18M | -$56M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$876M | $149M | -$59M | $216M | -$131M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$29M | -$17M | -$12M | -$11M | $0 |
| Other Financing | $941M | $35M | -$10M | -$15M | -$18M |
| Financing Cash Flow | $36M | $166M | -$81M | $190M | -$149M |
| Net Change in Cash | $301M | $240M | -$126M | $357M | -$148M |
| Cash End of Period | $555M | $795M | $669M | $1.0B | $881M |
| Free Cash Flow | $70M | -$11M | $22M | $110M | $23M |